S

Synthaverse SA
WSE:SVE

Watchlist Manager
Synthaverse SA
WSE:SVE
Watchlist
Price: 4.14 PLN -2.47% Market Closed
Market Cap: 293m PLN
Have any thoughts about
Synthaverse SA?
Write Note

Synthaverse SA
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Synthaverse SA
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
S
Synthaverse SA
WSE:SVE
Current Portion of Long-Term Debt
zł21.2m
CAGR 3-Years
53%
CAGR 5-Years
19%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Current Portion of Long-Term Debt
zł1.7m
CAGR 3-Years
-54%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
R
Read Gene SA
WSE:RDG
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genomed SA
WSE:GEN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Current Portion of Long-Term Debt
zł43.3m
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
-9%
U
Urteste SA
WSE:URT
Current Portion of Long-Term Debt
zł315k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Synthaverse SA
Glance View

Market Cap
292m PLN
Industry
Biotechnology

Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 234 full-time employees. The company went IPO on 2011-07-29. The firm focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The firm offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The firm supplies its products to 50 countries around the world.

SVE Intrinsic Value
6.96 PLN
Undervaluation 40%
Intrinsic Value
Price
S

See Also

What is Synthaverse SA's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
21.2m PLN

Based on the financial report for Jun 30, 2024, Synthaverse SA's Current Portion of Long-Term Debt amounts to 21.2m PLN.

What is Synthaverse SA's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
19%

Over the last year, the Current Portion of Long-Term Debt growth was 144%. The average annual Current Portion of Long-Term Debt growth rates for Synthaverse SA have been 53% over the past three years , 19% over the past five years .

Back to Top